为解决危重症恶性肿瘤患儿 HLH 早期诊断难题，研究发现 CD38 + HLA-DR + CD8 + T 细胞 % 和 IFN-γ 对此有诊断价值 ... 满足发热、血细胞减少、脾肿大、高甘油三酯血症或低纤维蛋白原血症、噬血细胞现象、NK 细胞功能障碍以及铁蛋白和可溶性白细胞介素 - 2 受体 ...

为解决皮肤 T 细胞淋巴瘤（CTCL）治疗难题，研究人员探究 CD38 作用及联合疗法，发现联合治疗可提升疗效。 皮肤 T 细胞淋巴瘤（Cutaneous T-Cell Lymphoma，CTCL）是一种让人头疼的非霍奇金淋巴瘤，它专门 “攻击” 皮肤里的恶性 T 细胞。得了这种病，患者皮肤状况 ...

CAR NK cells are following closely behind. Cytovia has designed CAR NK cells against three targets: EGFR, GPC3 and CD38. The EGFR candidate is a dual-targeted CAR designed to hit both wild-type ...

ONK’s subsequent NK-cell therapy, ONKT102, has a CD38 CAR with optimised affinity and a DR5 TRAIL variant. ONKT102 is designed to treat relapsed or refractory multiple myeloma (MM), a highly ...

Natural killer (NK) cells are the human body’s first line of defense against cancer and infections but tend to get knocked down by treatment with anti-CD38 antibodies. This is because NK cells ...

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month ...

an allogeneic CAR T-cell therapy targeting CD38, has administered the first dose to a patient in an investigator-initiated trial (IIT). THANK (Target to Hinder the Attack of NK cells)-uCAR® is ...

The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA. Feb 13, 2025 8:39am ET COEPTIS Announces the ...

Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...